RT Journal Article
SR Electronic
T1 SARS-CoV-2 spread across the Colombian-Venezuelan border
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.09.20149856
DO 10.1101/2020.07.09.20149856
A1 Paniz-Mondolfi, Alberto
A1 Muñoz, Marina
A1 Florez, Carolina
A1 Gomez, Sergio
A1 Rico, Angelica
A1 Pardo, Lisseth
A1 Barros, Esther C.
A1 Hernández, Carolina
A1 Delgado, Lourdes
A1 Jaimes, Jesús E.
A1 Pérez, Luis
A1 Teherán, Aníbal A.
A1 Alshammary, Hala Alejel
A1 Obla, Ajay
A1 Khan, Zenab
A1 Gonzalez-Reiche, Ana S.
A1 Hernandez, Matthew M.
A1 Sordillo, Emilia Mia
A1 Simon, Viviana
A1 van Bakel, Harm
A1 Ramírez, Juan David
YR 2020
UL http://medrxiv.org/content/early/2020/07/10/2020.07.09.20149856.abstract
AB Introduction Venezuela and Colombia both adopted measures of containment early in response to the COVID-19 pandemic. However, Venezuela’s ongoing humanitarian crisis has decimated its health care system, and forced millions of Venezuelans to flee through its porous border with Colombia. The extensive shared border, and illegal cross-border transit through improvised trails between the two countries are major challenges for public health authorities. We report the first SARS-CoV-2 genomes from Venezuela, and present a snapshot of the SARS-CoV-2 epidemiologic landscape in the Colombian-Venezuelan border region.Methods We sequenced and assembled viral genomes from total RNA extracted from nasopharyngeal (NP) clinical specimens using a custom reference-based analysis pipeline. Three assemblies obtained were subjected to typing using the Phylogenetic Assignment of Named Global Outbreak LINeages ‘Pangolin’ tool. A total of 376 publicly available SARS-CoV-2 genomes from South America were obtained from the GISAID database to perform comparative genomic analyses. Additionally, the Wuhan-1 strain was used as reference.Results We found that two of the SARS-CoV-2 genomes from Venezuela belonged to the B1 lineage, and the third to the B.1.13 lineage. We observed a point mutation in the Spike protein gene (D614G substitution), previously reported to be associated with increased infectivity, in all three Venezuelan genomes. An additional three mutations (R203K/G204R substitution) were present in the nucleocapsid (N) gene of one Venezuelan genome.Conclusions Genomic sequencing demonstrates similarity between SARS-CoV-2 lineages from Venezuela and viruses collected from patients in bordering areas in Colombia and from Brazil, consistent with cross-border transit despite administrative measures including lockdowns. The presence of mutations associated with increased infectivity in the 3 Venezuelan genomes we report and Colombian SARS-CoV-2 genomes from neighboring borders areas may pose additional challenges for control of SARS-CoV-2 spread in the complex epidemiological landscape in Latin American countries. Public health authorities should carefully follow the progress of the pandemic and its impact on displaced populations within the region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the University of Glasgow, Scottish Funding Council and the Global Challenges Research Fund (GCRF) and GCRF Research Network EP/T003782/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The INS is the reference lab and health authority of the national network of laboratories. In case of a public health emergency or when scientific research in public health is required, the national law 9-1979, decrees 786-1990 and 2323-2006, authorizes the INS to use the biological material and associated epidemiological information without informed consent, including the anonymous disclosure of results. This study was performed following the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments. The information used for this study comes from secondary sources of data that were anonymized and do not represent a risk to the community.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available within the manuscript.